Immunomod

Corporate Strategy

Our business strategy is threefold:

• Develop a robust product portfolio:
  We will continue to build and grow a strong pipeline of development candidates through the expertise of our scientific founders, research collaboration with MUSC, and targeted in-licensing.
• Attract strategic capital and distribution partners:
  At critical success milestones in our clinical trials, we will seek strategic capital and distribution partners to expand our trials and/or deliver products to market.
• Exit or harvest wisely:
  Delivering novel, effective, patent protected therapeutics to the marketplace will provide us with numerous opportunities to harvest or exit a product. We anticipate potential opportunities for mass product distribution, single product acquisitions, portfolio acquisitions, product out-licensing, as well as a potential future sale of the company. Our mission is to alleviate human suffering caused by diabetes and related auto-immune disorders, and we will explore attractive exit opportunities that allow us to meet this goal and those of our partners.